UCB SA (OTCMKTS:UCBJF – Get Free Report) hit a new 52-week high during mid-day trading on Thursday . The company traded as high as $184.00 and last traded at $184.00, with a volume of 0 shares. The stock had previously closed at $184.00.
UCB Stock Performance
The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33. The company’s 50-day moving average is $179.47 and its 200 day moving average is $153.52.
About UCB
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
Further Reading
- Five stocks we like better than UCB
- Transportation Stocks Investing
- Battle of the Retailers: Who Comes Out on Top?
- Low PE Growth Stocks: Unlocking Investment Opportunities
- HCA Healthcare: Temporary Setbacks, Long-Term Strength
- What Makes a Stock a Good Dividend Stock?
- MarketBeat Week in Review – 10/28 – 11/1
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
